Dumontet et al., using data from the FIRST trial, where lenalidomide and dexamethasone were compared to melphalan–prednisone–dexamethasone (MPT) in transplant-ineligible NDMM patients, included hemoglobin levels, along with ECOG performance status, lactate dehydrogenase, and serum β2-microglobulin, in a model predicting first treatment-emergent grade 3 infections within the initial four months of treatment [46]. Here, HLA-G is linked to infection.